Announcements
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
More ▼
Key statistics
On Friday, argenx SE (1AEA:STU) closed at 338.00, -15.50% below its 52-week high of 400.00, set on Nov 01, 2022.
52-week range
Markit short selling activity
Open | 338.00 |
---|---|
High | 338.00 |
Low | 338.00 |
Bid | 340.00 |
Offer | 346.00 |
Previous close | 344.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 55.47m |
Free float | 54.74m |
P/E (TTM) | -- |
Market cap | 20.75bn USD |
EPS (TTM) | -17.47 USD |
Data delayed at least 15 minutes, as of Feb 03 2023.
More ▼